Characterization of patients with Duchenne muscular dystrophy across previously developed health states
Open Access
- 30 October 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0307118
Abstract
Project HERCULES has developed a natural history model (NHM) of disease progression in Duchenne muscular dystrophy (DMD) that comprises eight ordered health states (two ambulatory states, one transfer state indicating increased caregiver burden in which patients cannot walk/run 10m or rise from floor but can still support their own weight, and five non-ambulatory states). The current study used data from nine sources (clinical trial placebo arms, one real-world dataset, and three natural history datasets) to further characterize patients with DMD according to these health states. The study included 1,173 patients across 5,306 visits. Patients were on average older and exhibited worse ambulatory, pulmonary, upper limb, and cardiac functions with each successive health state. Mean±SE ages increased monotonically across health states, starting with 8.47±0.07 for early ambulatory, 10.86±0.13 for late ambulatory, 11.65±0.35 for transfer state, and ranging from 13.17±0.32 to 16.84±0.37 for the non-ambulatory states. North Star Ambulatory Assessment (NSAA) total score, which measures motor function and ranges from 34 (best) to 0 (worst), was 23.7 (interquartile range [IQR]: 20–30) for early ambulatory patients, 12.7 (IQR: 9–16) for late ambulatory patients, and 3.9 (IQR: 2–5) for transfer patients. Pulmonary function as measured by mean±SE of forced vital capacity percent predicted (FVC%p) was 94.5±0.8 for early ambulatory, 89.1±1.4 for late ambulatory, and 80.2±2.8 for transfer states, and decreased from 77.2±1.7 to 20.6±1.6 across the five non-ambulatory health states. In summary, these findings further characterize health states and their interpretation in economic modeling and decision-making in DMD management.Keywords
Funding Information
- Collaborative Trajectory Analysis Project
- Pfizer, Inc.
This publication has 34 references indexed in Scilit:
- Developing a Natural History Model for Duchenne Muscular DystrophyPharmacoEconomics - Open, 2023
- Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controlsNeuromuscular Disorders, 2022
- One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failureEuropean Journal of Epidemiology, 2021
- Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular DystrophyChest, 2020
- Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysisEuropean Journal of Epidemiology, 2020
- EP.41Project HERCULES: could international collaboration on value assessment change clinical practice?Neuromuscular Disorders, 2019
- Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoidsNeuromuscular Disorders, 2018
- Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort studyThe Lancet, 2018
- Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011Annals of Physical and Rehabilitation Medicine, 2013
- Development of a Functional Assessment Scale for Ambulatory Boys with Duchenne Muscular DystrophyPhysiotherapy Research International, 2011